Founded in 2013 at UCSD by Dr. Messmer and Dr. Kipps, Abreos has the exclusive license to the issued patent for developing point-of-care devices that monitor the levels of biologic drugs in patients for precision dose guidance. With this capability, patients can ensure they are receiving and maintaining the right amount of these expensive and efficacious medications, enabling better outcomes at a lower cost. Abreos has developed tests for the top biologic drugs used in autoimmune and neurology disorders, and cancer.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/30/16 | undisclosed | Seed |
Triton Technology Fund Vertical Venture Partners | undisclosed |
